B. Riley Issues Pessimistic Estimate for Novavax Earnings

Novavax, Inc. (NASDAQ:NVAX) – Investment analysts at B. Riley lowered their Q1 2025 EPS estimates for Novavax in a note issued to investors on Monday, March 3rd. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will earn ($0.46) per share for the quarter, down from their prior forecast of ($0.38). The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share. B. Riley also issued estimates for Novavax’s Q2 2025 earnings at $0.64 EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($0.78) EPS, FY2026 earnings at $0.11 EPS, FY2027 earnings at $0.61 EPS, FY2028 earnings at $0.59 EPS and FY2029 earnings at $1.36 EPS.

NVAX has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $19.00 price target on shares of Novavax in a research report on Tuesday, December 10th. TD Cowen raised shares of Novavax to a “hold” rating in a report on Thursday, February 27th. Finally, BTIG Research started coverage on shares of Novavax in a report on Friday, February 28th. They issued a “buy” rating and a $19.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $18.00.

Novavax Stock Up 2.7 %

NVAX opened at $7.89 on Wednesday. The company has a 50 day moving average of $8.47 and a two-hundred day moving average of $9.86. Novavax has a 52-week low of $3.81 and a 52-week high of $23.86. The company has a market cap of $1.26 billion, a P/E ratio of -3.49, a P/E/G ratio of 2.85 and a beta of 2.14.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.24. The business had revenue of $88.31 million during the quarter, compared to analysts’ expectations of $85.48 million. During the same quarter last year, the firm earned ($1.44) earnings per share.

Hedge Funds Weigh In On Novavax

Several institutional investors and hedge funds have recently made changes to their positions in the company. E Fund Management Co. Ltd. grew its holdings in Novavax by 5.1% during the fourth quarter. E Fund Management Co. Ltd. now owns 25,340 shares of the biopharmaceutical company’s stock worth $204,000 after buying an additional 1,219 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Novavax by 38.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 1,598 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Novavax by 0.4% during the fourth quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company’s stock valued at $3,509,000 after buying an additional 1,664 shares during the period. Victory Capital Management Inc. raised its stake in Novavax by 12.0% in the third quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 2,072 shares in the last quarter. Finally, Federated Hermes Inc. grew its position in Novavax by 4.4% in the fourth quarter. Federated Hermes Inc. now owns 50,506 shares of the biopharmaceutical company’s stock worth $406,000 after acquiring an additional 2,124 shares in the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Insiders Place Their Bets

In other news, Director James F. Young sold 4,600 shares of Novavax stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total value of $39,008.00. Following the sale, the director now directly owns 57,160 shares in the company, valued at $484,716.80. This trade represents a 7.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Rachel K. King sold 4,150 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $9.02, for a total transaction of $37,433.00. Following the sale, the director now directly owns 14,770 shares in the company, valued at $133,225.40. This trade represents a 21.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,150 shares of company stock worth $119,641 over the last quarter. Company insiders own 1.00% of the company’s stock.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.